Radiation Oncology

Doç. Dr. Berrin Yalçın

Doctor and researcher İstanbul Eğitim Araştırma Hastanesi İstanbul
Prostatic NeoplasmsUrinary Bladder NeoplasmsAdenocarcinoma
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Prostatic Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Urinary Bladder Neoplasms 2 publications
  • Adenocarcinoma 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyRadiation Oncologysaglik.gov.trFrom source
  • Institutionİstanbul Eğitim Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workProstatic NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications15 publicationsOpenAlex, ORCIDFrom source
  • ORCID0000-0002-6354-4609ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://istanbuleah.saglik.gov.tr/TR-1039866/doktorlar.html#berrin-yalcinsaglik.gov.tr

Scientific work

Publications on Prostatic Neoplasms

15 publications

  1. Survival in Synchronous Versus Metachronous Bladder and Prostate Cancer

    Archivos Españoles de Urología, 2026

    DOI 10.56434/j.arch.esp.urol.20267905.93 PMID 42438875 Open-access full textSource: OpenAlex

  2. Qualitative Interferon-γ Release Assay for Predicting Response to BCG Instillations in Bladder Cancer

    Archivos Españoles de Urología, 2025

    DOI 10.56434/j.arch.esp.urol.20257808.133 PMID 41111372 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  3. Predictive Value of Systemic Inflammatory Markers in the Prognosis of Prostate Cancer with Variant Histology.

    Urology journal./Urology jornal., 2025

    DOI 10.22037/uj.v22i.8378 PMID 40684276 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  4. Survival in Synchronous Versus Metachronous Bladder & Prostate Cancer

    Research Square, 2025

    DOI 10.21203/rs.3.rs-7579205/v1 Open-access full textSource: ORCID

  5. Hemoglobin Level as a Prognostic Factor of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer

    Istanbul Medical Journal, 2024

    DOI 10.4274/imj.galenos.2024.35902 1 citation (OpenAlex) Open-access full textSource: ORCID

  6. Qualitative Interferon-γ Release Assay for Predicting Response to BCG instillations in Bladder Cancer

    Research Square, 2024

    DOI 10.21203/rs.3.rs-4357424/v1 Open-access full textSource: ORCID

  7. Synchronous/Metachronous Bilateral Breast Cancer: a Long-Term Follow-up Single-Center Experience

    Indian Journal of Surgery, 2024

    DOI 10.1007/s12262-023-03965-z 1 citation (OpenAlex) Source: ORCID

  8. Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma.

    Urology journal./Urology jornal., 2023

    DOI 10.22037/uj.v20i.7468 PMID 36840448 Open-access full textSource: OpenAlex

  9. Radiotherapy for benign diseases in Turkey: a patterns of care survey of the Turkish Society for Radiation Oncology (TROD 05-002)

    Strahlentherapie und Onkologie, 2023

    DOI 10.1007/s00066-023-02154-x PMID 37796342 3 citations (Europe PMC) Source: OpenAlex

  10. Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

    UROLOGY JOURNAL, 2023

    DOI 10.22037/uj.v20i.7468] Source: ORCID

View all 15 publications